These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 36661694)
21. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. Aggarwal C; Thompson JC; Black TA; Katz SI; Fan R; Yee SS; Chien AL; Evans TL; Bauml JM; Alley EW; Ciunci CA; Berman AT; Cohen RB; Lieberman DB; Majmundar KS; Savitch SL; Morrissette JJD; Hwang WT; Elenitoba-Johnson KSJ; Langer CJ; Carpenter EL JAMA Oncol; 2019 Feb; 5(2):173-180. PubMed ID: 30325992 [TBL] [Abstract][Full Text] [Related]
22. Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer. Benavides M; Alcaide-Garcia J; Torres E; Gil-Calle S; Sevilla I; Wolman R; Durán G; Álvarez M; Reyna-Fortes C; Ales I; Pereda T; Robles M; Kushnir M; Odegaard J; Faull I; Alba E ESMO Open; 2022 Jun; 7(3):100481. PubMed ID: 35525184 [TBL] [Abstract][Full Text] [Related]
23. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770 [TBL] [Abstract][Full Text] [Related]
24. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia. Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856 [TBL] [Abstract][Full Text] [Related]
25. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC). Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593 [TBL] [Abstract][Full Text] [Related]
26. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949 [TBL] [Abstract][Full Text] [Related]
27. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999 [TBL] [Abstract][Full Text] [Related]
28. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Guibert N; Hu Y; Feeney N; Kuang Y; Plagnol V; Jones G; Howarth K; Beeler JF; Paweletz CP; Oxnard GR Ann Oncol; 2018 Apr; 29(4):1049-1055. PubMed ID: 29325035 [TBL] [Abstract][Full Text] [Related]
29. Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors. Yousefi B; LaRiviere MJ; Cohen EA; Buckingham TH; Yee SS; Black TA; Chien AL; Noël P; Hwang WT; Katz SI; Aggarwal C; Thompson JC; Carpenter EL; Kontos D Sci Rep; 2021 May; 11(1):9984. PubMed ID: 33976268 [TBL] [Abstract][Full Text] [Related]
30. Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data. Chen H; Wang A; Wang J; He Z; Mao Y; Liu L J Cancer Res Clin Oncol; 2020 Jul; 146(7):1867-1876. PubMed ID: 32221744 [TBL] [Abstract][Full Text] [Related]
31. CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer. Prabhash K; Biswas B; Khurana S; Batra U; Biswas G; Advani SH; Mohapatra PN; Rajappa S; Sharma A; Patil S; Dattatreya PS; Roy R; Almel S; Goyal G; Warrier N Indian J Cancer; 2022 Mar; 59(Supplement):S11-S18. PubMed ID: 35343188 [TBL] [Abstract][Full Text] [Related]
32. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer. Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341 [TBL] [Abstract][Full Text] [Related]
33. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples. Ma C; Yang X; Xing W; Yu H; Si T; Guo Z Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608 [TBL] [Abstract][Full Text] [Related]
34. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer. Nesline MK; Subbiah V; Previs RA; Strickland KC; Ko H; DePietro P; Biorn MD; Cooper M; Wu N; Conroy J; Pabla S; Zhang S; Wallen ZD; Sathyan P; Saini K; Eisenberg M; Caveney B; Severson EA; Ramkissoon S Oncol Ther; 2024 Jun; 12(2):329-343. PubMed ID: 38502426 [TBL] [Abstract][Full Text] [Related]
35. Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung Cancer. Fernandes MGO; Cruz-Martins N; Souto Moura C; Guimarães S; Pereira Reis J; Justino A; Pina MJ; Magalhães A; Queiroga H; Machado JC; Hespanhol V; Costa JL Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070940 [TBL] [Abstract][Full Text] [Related]
36. Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial. Han X; Tang X; Zhu H; Zhu D; Zhang X; Meng X; Hua Y; Wang Z; Zhang Y; Huang W; Wang L; Yuan S; Zhang P; Gong H; Sun Y; Zhang Y; Liu Z; Dong X; Gai F; Huang Z; Zhu C; Guo J; Wang Z J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600554 [TBL] [Abstract][Full Text] [Related]
37. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC. Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817 [TBL] [Abstract][Full Text] [Related]
38. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. Kwon M; Ku BM; Olsen S; Park S; Lefterova M; Odegaard J; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Cancer Med; 2022 Aug; 11(15):2944-2956. PubMed ID: 35437925 [TBL] [Abstract][Full Text] [Related]
39. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719 [TBL] [Abstract][Full Text] [Related]
40. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay. Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]